Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Nucleic Acids Res ; 52(12): 6994-7011, 2024 Jul 08.
Artigo em Inglês | MEDLINE | ID: mdl-38828775

RESUMO

The clinical success of PARP1/2 inhibitors (PARPi) prompts the expansion of their applicability beyond homologous recombination deficiency. Here, we demonstrate that the loss of the accessory subunits of DNA polymerase epsilon, POLE3 and POLE4, sensitizes cells to PARPi. We show that the sensitivity of POLE4 knockouts is not due to compromised response to DNA damage or homologous recombination deficiency. Instead, POLE4 loss affects replication speed leading to the accumulation of single-stranded DNA gaps behind replication forks upon PARPi treatment, due to impaired post-replicative repair. POLE4 knockouts elicit elevated replication stress signaling involving ATR and DNA-PK. We find POLE4 to act parallel to BRCA1 in inducing sensitivity to PARPi and counteracts acquired resistance associated with restoration of homologous recombination. Altogether, our findings establish POLE4 as a promising target to improve PARPi driven therapies and hamper acquired PARPi resistance.


Assuntos
Proteína BRCA1 , DNA Polimerase II , Replicação do DNA , Inibidores de Poli(ADP-Ribose) Polimerases , Inibidores de Poli(ADP-Ribose) Polimerases/farmacologia , Humanos , Proteína BRCA1/genética , Proteína BRCA1/metabolismo , DNA Polimerase II/metabolismo , DNA Polimerase II/genética , Replicação do DNA/efeitos dos fármacos , Dano ao DNA , Linhagem Celular Tumoral , Recombinação Homóloga/genética , Recombinação Homóloga/efeitos dos fármacos , Resistencia a Medicamentos Antineoplásicos/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...